Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Personalized Medicine: A Search for Tailored Therapeutics


for Members

Personalized Medicine: A Search for Tailored Therapeutics

Tuesday, September 20, 2011

The New York Academy of Sciences

With increasingly sophisticated profiling techniques, physicians and pharmaceutical investigators now appreciate the inherent complexity of disease in individual patients and the unique sensitivity of each patient to specific therapeutic treatments. This understanding has spurred the development of methods to improve the ability to determine the unique cause of a disease symptom and thus to better predict the effect of specific therapeutic intervention in successfully treating this indication. In this symposium we will review the new technologies currently being used to profile the unique causes of human disease, including quantitative genomic changes that result in abnormal protein expression in disease, advances in quantitative proteomics, clinical screening data, and advancing technologies within the biotech arena that may ultimately make personalized medicine a reality.

This event will also be broadcast as a webinar.

Please note: Transmission of presentations via the webinar is subject to individual consent by the speakers. Therefore, we cannot guarantee that every speaker's presentation will be broadcast in full via the webinar. To access all speakers' presentations in full, we invite you to attend the live event in New York City, where possible.

Networking reception to follow.

Registration Pricing

Student / Postdoc / Fellow Member:$0
Student / Postdoc / Fellow Nonmember:$15


The Biochemical Pharmacology Discussion Group is proudly sponsored by


Mission Partner support for the Frontiers of Science program provided by



* Presentation times are subject to change.

Tuesday, September 20, 2011

12:30 PM


1:00 PM

Charles A. Lunn, PhD, Merck Research Laboratories

1:10 PM

Noninvasive Personalized Genomics
Charles R. Cantor, PhD, Sequenom Inc.

1:50 PM

Network Biology Classifiers for Network Prediction
Mark R. Chance, PhD, Case Western Reserve University

2:30 PM

Epigenetics: How Genes and Environment Interact
Randy L. Jirtle, PhD, Duke University Medical Center

3:10 PM

Coffee Break

3:40 PM

Towards Comprehensive Somatic Pharmacogenomics of Lung Cancer for Personalized Oncology
Marc Ladanyi, MD, Memorial Sloan-Kettering Cancer Center

4:20 PM

Panel Discussion
Moderator: Ann del Campo, MS, PhD, Sequenom Inc.

5:00 PM

Networking Reception

6:00 PM

Program Ends



Ann del Campo, MS, PhD

Sequenom Inc.

Ann del Campo received her BS degree in biology and chemistry from St. Joseph College in West Hartford, CT, in 1977 and completed her MS and PhD degree in experimental pathology from the University of Southern California LAC-USC Medical Campus in 1984. Following work at Cedars-Sinai Medical Center in Beverly Hills, CA, she joined industry and was quickly recognized as an “ambassador” to work with other company representatives in Industry who needed technical expertise and marketable presentations. In 1989, she Joined Amersham Life Sciences and then GE Healthcare for an 18-year tenure bringing new technologies to market, including Proteomics, High Throughput Screening, Custom Preparations for ADME, and live cell imaging technologies within pharmaceutical companies and academic centers of excellence. During this time she received numerous awards for excellence in industry. Del Campo is currently a senior business development manager at Sequenom, Inc., and works with well recognized scientists in translational sciences and biomarker validation studies to enable more tailored health care treatments for patients in oncology and other diseases where genomic signatures can enable improved outcomes. She has served as a member of the Society for Laboratory Automation and Screening's Education Advisory Committee and is working in her local community to promote student mentorship programs with local schools to engage students and their families in healthier lifestyles by connecting them to local farms.

Charles A. Lunn, PhD

Merck Research Laboratories

Charles A. Lunn received his BA and PhD degrees from Johns Hopkins University in Baltimore, MD, in 1985. Following postdoctoral training at SUNY Stony Brook, he joined Schering-Plough's Department of Immunology, with a focus on novel immune modulators. He joined the New Lead Discovery group at Schering-Plough in 2004 and retained this position when Schering-Plough and Merck merged in 2009. Lunn's 50 publications include editing the book Membrane Proteins as Drug Targets, part of Elsevier's Progress in Molecular Biology and Translational Science series. He is currently a research fellow with the department of In Vitro Pharmacology at Merck Research Laboratories in Kenilworth, NJ. Lunn is also program coordinator for the Biochemical Pharmacology Steering Committee at the New York Academy of Sciences and a member of the Society for Laboratory Automation and Screening's Education Advisory Committee.

Jennifer Henry, PhD

The New York Academy of Sciences


Charles R. Cantor, PhD

Sequenom Inc.

Charles Cantor is a founder and Chief Scientific Officer at SEQUENOM, Inc., a genetics discovery company with tools, information, and strategies for determining the medical impact of genes and genetic variations. He is also founder of SelectX Pharmaceuticals, a drug discovery company; Retrotope, an anti-aging company; and Dithera, a biotherapeutic company. Cantor is professor emeritus in biomedical engineering and pharmacology and was the director of the Center for Advanced Biotechnology at Boston University. He is adjunct professor of bioengineering at the University of California San Diego, adjunct professor of molecular biology at the Scripps Institute for Research, and distinguished adjunct professor of physiology and biophysics at the University of California Irvine. Prior to this, Cantor held positions at Columbia University and the University of California at Berkeley. He was also the director of the Human Genome Center Project of the Department of Energy at Lawrence Berkeley Laboratory. Cantor has been granted 60 U.S. patents and wrote a three-volume textbook on biophysical chemistry. He coauthored the first textbook on genomics, titled The Science and Technology of the Human Genome Project. In addition, he sits on the advisory boards of more than 15 national and international biotechnology firms, has published more than 450 peer-reviewed articles, and is a member of the National Academy of Sciences.

Mark R. Chance, PhD

Case Western Reserve University

Mark Chance is professor of general medical sciences, Director of the Center for Proteomics and Bioinformatics, and professor and interim chair of the Department of Genetics at the Case Western Reserve University School of Medicine. Chance received his PhD in biophysics from the University of Pennsylvania in 1986. He spent a large portion of his career teaching at the Albert Einstein College of Medicine prior to joining the Case Western Reserve University School of Medicine and the Center for Proteomics and Bioinformatics in 2005. The Chance lab uses quantitative mass spectrometry and 2-D gel techniques in order to identify biomarkers and regulatory pathways in complex diseases such as cancer, diabetes, and HIV infection. A major emphasis is placed on applying state-of-the art proteomics and systems biology tools to investigate HIV pathogenesis in the context of drug abuse, and provide significant biomarkers of cancer progression and response to therapy. The use of high-resolution mass spectrometry instruments of the Center, coupled with the advanced bioinformatics and biostatistical pipelines for analysis, provide quantitative label free protein expression analysis using a "shotgun" proteomics approach. Subsequent analysis using network and pathway tools provide novel insights into patho-physiological changes in disease. Chance has received numerous awards, including the Upjohn Company New Faculty Research Award and the Irma T. Hirschl Career Scientist Award. He has also published over 200 manuscripts on his proteomics, mass spectrometry, and bioinformatics research.

Randy L. Jirtle, PhD

Duke University Medical Center

Randy L. Jirtle is a professor of radiation oncology and an associate professor of pathology at Duke University, Durham, NC, where he has been a faculty member since 1977. He graduated with a BS degree in nuclear engineering in 1970 and a PhD degree in radiation biology in 1976, both from the University of Wisconsin-Madison. Jirtle's research interests are in epigenetics, genomic imprinting, and the fetal origins of disease susceptibility. Jirtle holds two U.S. patents on imprinted genes, and another one is pending approval. He has published over 170 peer-reviewed articles, including 10 publications featured on journal covers. He was also a featured scientist on the NOVA and ScienceNow television programs on epigenetics and on National Public Radio programs The People's Pharmacy, The DNA Files, SQ Radio, and The Leonard Lopate Show: Please Explain. He has delivered numerous endowed lectures and was invited to present his research at the 2004 Nobel Symposium on Epigenetics. He was honored in 2006 with the Distinguished Achievement Award from the College of Engineering at the University of Wisconsin-Madison. In 2007 Jirtle received an Esther B. O'Keeffe Charitable Foundation Award and capped off the year with a nomination for Time Magazine's Person of the Year. He was the inaugural recipient of the Epigenetic Medicine Award in 2008 and received the STARS Lecture Award in Nutrition and Cancer from the National Cancer Institute in 2009. In 2010 he was invited to participate in the launch meeting of the International Human Epigenome Consortium (IHEC) in Paris, the Aspen Ideas Festival in Colorado, and Nestlé's Seventh International Nutrition Symposium in Switzerland. Jirtle was invited this year to speak at the Epigenomics in Clinical Medicine Symposium sponsored by The Nobel Assembly at Karolinska Institutet in Stockholm.

Marc Ladanyi, MD

Memorial Sloan-Kettering Cancer Center

Marc Ladanyi received his MD from McGill University in Montreal and is presently Attending Pathologist in Molecular Diagnostics Service of the Department of Pathology and a member in the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center (MSKCC) in New York. In 2004, as head of the clinical molecular diagnostic laboratories at MSKCC, Ladanyi established rapid and sensitive EGFR mutation detection assays that allowed early implementation of tumor mutation testing, making the discovery of EGFR mutations in lung cancer immediately relevant to the routine care of lung cancer patients. Beyond EGFR mutation testing, Ladanyi has also been a leader in recent efforts to introduce into routine practice even broader large-scale screening of lung cancer tumor specimens for additional mutations that can be targets for new drugs. His research laboratory is focused on the genomics and molecular pathogenesis of sarcomas and thoracic malignancies, including lung adenocarcinomas and mesothelioma. Ladanyi has received the Young Investigator Award from the U.S. and Canadian Academy of Pathology (2005) and was awarded the Nina Axelrod Lectureship by the Connective Tissue Oncology Society (2007) and the Caine Halter Hope Now Award from Uniting Against Lung Cancer (2009). In 2010 he was also appointed to the William Ruane Chair in Molecular Oncology at MSKCC. He has authored or coauthored over 200 primary research papers and over 40 reviews and commentaries.


For sponsorship opportunities please contact Carmen McCaffery at or 212.298.8642.

The Biochemical Pharmacology Discussion Group is proudly sponsored by


Grant Support

Supported by an educational grant from Genentech, Inc. and Gilead, Inc.

This activity is supported by an educational donation provided by Amgen.

This activity is supported in part by New England Biolabs.

Academy Friends

Bristol-Myers Squibb

Promotional Partners

Biocat (The BioRegion of Catalonia)

Biomarker Commons

Personalized Medicine Coalition

Mission Partner support for the Frontiers of Science program provided by


Mission Partner support for the Frontiers of Science program provided by ACS

Mission Partner support for the Frontiers of Science program provided by   ACS


Noninvasive Personalized Genomics
Charles R. Cantor, Sequenom Inc.

Second generation DNA sequencing and DNA mass spectrometry provide complementary, synergistic ways of analyzing nucleic acids in patient samples like blood plasma that can be obtained non-invasively. Sequencing is best where large genomic regions or even the entire genome must be scanned and where the analytes of interest exist in a relatively narrow concentration range. Mass spectrometry is best where at most a few hundred loci need to be examined, but high sensitivity or high dynamic range are required. Examples will be shown in a number of areas, including non-invasive prenatal diagnostics by plasma analysis and detection of somatic oncogene mutations in various clinical samples. A pilot study in which an entire fetal genome was sequenced from maternal plasma will also be described. The implications of this study are that once sequencing costs are inevitably reduced, there is almost no limit to the amount of personal genomic information that can be obtained non-invasively.

Network Biology Classifiers for Network Prediction
Mark R. Chance, PhD, Case Western Reserve University

Systems biology has paved the way for systems medicine, where the goal is to provide more accurate and predictive models of the patho-physiology of complex diseases, as well as define healthy states. The reason is clear: we want accurate models that will lead to more specific and sensitive markers of disease in order to help clinicians better stratify their patient populations and optimize treatment plans. In addition, we expect that these models will aid the identification of novel drug targets to combat disease and provide basic researchers with bioinformatics tools to drive fruitful research. However, for many complex diseases, particularly at the clinical level, it is becoming increasingly clear that one or a few genomic variations alone (e.g., simple models) cannot adequately explain the multiple phenotypes related to disease states or the variable risks that attend disease progression. Models that account for the activities of many interacting proteins (sub-networks) explain a wider range of variability inherent in these phenotypes. These models, which encompass protein–protein interaction (PPI) networks dysregulated for specific diseases and specific patient subpopulations, are constructed by integrating various information within the global PPI network with multiple types of other relevant cellular information (e.g., gene expression, proteomics, SNPs, etc.). PPI networks are thus playing an increasingly important role in investigating systems medicine and complex human diseases. These networks present us with a static but highly functional view of the cellular state and thus give us a better understanding of not only the normal phenotype, but also the overall disease phenotype at the level of the whole organism when certain interactions become dysregulated. We will describe and present the results of several novel integrative approaches that combine global PPI networks, genome-wide expression data, mutations, and proteomic data to identify and score sub-networks in models of human colorectal cancer and glioblastoma multiforme. In addition, we show computational cross-validation of these sub-networks, where they provide excellent performance as classifiers, as well as independent validation of dysregulated expression of sub-network proteins in targeted proteomics experiments. The combinations of public data employed with novel algorithms to define subnetworks followed by targeted experimental proteomics provide a new paradigm to accelerate cancer biology research.

Epigenetics: How Genes and Environment Interact
Randy L. Jirtle, PhD, Duke University Medical Center

Human epidemiological and animal experimental data indicate that the risk of developing adult onset diseases and neurological disorders is influenced by persistent adaptations to prenatal and early postnatal nutrition. Two epigenetically regulated targets that potentially link environmental exposures early in development to adult diseases are imprinted genes and those with metastable epialleles. Genes with metastable epialleles have highly variable functions because of random allelic changes in the epigenome. Genomic imprinting is an unusual epigenetic form of gene regulation that evolved in mammals with the development of the placenta and the advent of live birth. It results in only one copy of a gene being expressed in a parent-of-origin dependent manner. Thus, a single genetic or epigenetic event is all that is required to alter the function of an imprinted gene. The potential importance of these two novel subsets of epigenetically labile genes in normal human variation and the etiology of environmentally-induced diseases will be discussed.

Towards Comprehensive Somatic Pharmacogenomics of Lung Cancer for Personalized Oncology
Marc Ladanyi, MD, Memorial Sloan-Kettering Cancer Center

Mutations in key components of the kinase signaling pathways have emerged as important predictive markers of sensitivity or resistance to agents that target these pathways in lung adenocarcinoma. Genotyping tumors for these mutations can direct the care of individual patients, pre-qualify them for upcoming trials, and aid research. Memorial Sloan-Kettering Cancer Center has been an early adopter in clinical mutation testing of solid tumors. Since 2004 our clinical laboratory has tested over 4000 lung adenocarcinomas for EGFR and KRAS mutations, more recently adding testing for the EML4-ALK fusion and other less common driver mutations in BRAF, HER2, and other genes. Based on our extensive genotyping data, we estimate that an actionable, targetable driver mutation can be identified in up to 66% of lung adenocarcinomas. The experience in lung adenocarcinoma now serves as a model for how mutational genotyping could benefit other major cancers.

Travel & Lodging

Our Location

The New York Academy of Sciences

7 World Trade Center
250 Greenwich Street, 40th floor
New York, NY 10007-2157

Directions to the Academy

Hotels Near 7 World Trade Center

Recommended partner hotel

Club Quarters, World Trade Center
140 Washington Street
New York, NY 10006
Phone: 212.577.1133

The New York Academy of Sciences is a member of the Club Quarters network, which offers significant savings on hotel reservations to member organizations. Located opposite Memorial Plaza on the south side of the World Trade Center, Club Quarters, World Trade Center is just a short walk to the Academy.

Use Club Quarters Reservation Password NYAS to reserve your discounted accommodations online.

Other nearby hotels

Millenium Hilton


Marriott Financial Center


Club Quarters, Wall Street


Eurostars Wall Street Hotel


Gild Hall, Financial District


Wall Street Inn


Ritz-Carlton New York, Battery Park